SCHEMBL22305381

SCHEMBL22305381

CC(C)(C)OC(=O)NCC(=O)NC(=N)S

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 2/20 0.36
TSHR P16473 2/20 0.36
CA2 P00918 4/20 0.35
CA12 O43570 3/20 0.35
CA14 Q9ULX7 1/20 0.35
APLNR P35414 1/20 0.35
CA1 P00915 3/20 0.35
CA9 Q16790 2/20 0.35
EPHX1 P07099 1/20 0.35
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
GLS O94925 1/20 0.34
NPFFR1 Q9GZQ6 1/20 0.34
NPFFR2 Q9Y5X5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23714991 0.84 TDP1 (0.42) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL6562046 0.79 TDP1 (0.37) TDP1MEN1KMT2AGAACA2
SCHEMBL8097883 0.77 TDP1 (0.48) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL18510209 0.77 TDP1 (0.42) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL10947963 0.77 TDP1 (0.42) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL20107158 0.77 TDP1 (0.42) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL17570621 0.76 TDP1 (0.41) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL1950351 0.76 TDP1 (0.47) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL18618701 0.76 TDP1 (0.47) TDP1MAOAMAOBMEN1KMT2A
SCHEMBL3677388 0.76 TDP1 (0.47) TDP1MAOAMAOBMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230149414-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. 2023-05-18 US disclosed
WO-2020160180-A1 COMPOUNDS AND USES THEREOF FOGHORN THERAPEUTICS INC. (US) 2020-08-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230149414-A1 COMPOUNDS AND USES THEREOF VHL, CLN6, TFEB TDP1 725/4885MAOA 2223/4885MAOB 975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.